多药耐药铜绿假单胞菌的耐药现状  

Current status of antibiotic resistance of multidrug-resistant Pseudomonas aeruginosa

作　　者：何晓雯[1] 王群兴[1] 周宜兰[1] 滕廷波[1] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院检验科,湖北宜昌443003

出　　处：《中华医院感染学杂志》2012年第7期1486-1487,共2页Chinese Journal of Nosocomiology

摘　　要：目的探讨医院多药耐药铜绿假单胞菌(MDRPA)的耐药特性,为临床医师合理使用抗菌药物提供实验室参考依据。方法细菌培养严格按照《全国临床检验操作规程》进行;细菌鉴定采用法国生物梅里埃公司提供的API板条和软件系统;采用K-B法进行药敏试验,结果评价依据CLSI最新版本。结果 205株MDRPA中泛耐药株检出率为12.7%;MDRPA对亚胺培南、美罗培南、哌啦西林/他唑巴坦、头孢哌酮/舒巴坦已产生了12.7%～15.1%的耐药率,对其他常用抗菌药物的耐药率为30.0%～71.0%,且耐药率呈上升趋势。结论医院务必加强抗菌药物使用管理,坚持进行细菌耐药性监测,遏制细菌耐药性快速增长的不良趋势。OBJECTIVE To investigate drug resistance of multidrug-resistant Pseudomonas aeruginosa （MDRPA） so as to provide the experimental evidence for clinically reasonable use of the antibiotics. METHODS Referring to National Guide to Clinical Laboratory Procedures, the strains were cultured. The API kits and relative software （France, M6rieux） were used to identify the strains. The susceptibility testing was performed by K-B methods. The testing results were assessed according to the latest version of CLSI. RESULTS Of 205 isolates of MDRPA, the detection rate of pandrug-resistant isolates was 12. 7% the resistance rates of MDRPA to imipenem, meropenem, piperacillin/tazobactam, and cefoperazone/sulbactam varied between 12. 7% and 15. 1 %, and the resistance rates to other common antibiotics showed increasing tendency, varying between 30.0% and 71.0%. CONCLUSION The hospital should strengthen the management of the antibiotic use and adhere the surveillance for the bacterial resistance so as to restrain the rapidly increasing tendency of antimicrobial resistance.

关 键 词：多药耐药 铜绿假单胞菌 医院感染 耐药性 管理 

分 类 号：R378.991[医药卫生—病原生物学]